Search contract descriptions, companies and agencies.
AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS. SARS COV-2
Total Committed
$2.64M
Product or Service Description
Biomedical Advanced Development R&D
Total Potential Value
$8.43M
Contracting Agency
Effective Date
March 29, 2018
Funding Department
NATIONAL INSTITUTES OF HEALTH NIAID
Type
Cost plus fixed fee
Solicitation Procedure
Negotiated proposal/quote
Extent Competed
Full and open competition
Recent Contract Actions 
Contracts can have multiple “contract actions”: This is how agencies spend money for a specific purpose, adjust the amount committed or change the contract in a way that doesn’t affect the amount. That last scenario is usually indicated by a $0 action. If there is a contract action for a negative amount, it generally means the contract was adjusted or canceled.
| Vendor | Description | Signed | Reason for Change | Amount Committed |
|---|---|---|---|---|
| HUMANETICS CORPORATION | IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS | Dec. 22, 2020 | Other Administrative Action | $0 |
| HUMANETICS CORPORATION | SUPPLEMENTAL WORK-SARS-COV-2 | July 21, 2020 | Supplemental Agreement For Work Within Scope | $2,137,190 |
| HUMANETICS CORPORATION | AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS. SARS COV-2 | June 22, 2020 | Supplemental Agreement For Work Within Scope | $503,859 |
About this data
This data comes from the Federal Procurement Data System, which includes all contracts worth $10,000 or more. We look at all contracts that are tagged with the procurement code for COVID-19 or otherwise started in 2020 and contain “COVID-19” in the description. Department of Defense contracting data is subject to a 90-day delay before it appears in the data.